Literature DB >> 25793246

[Brain metastases in pulmonary adenocarcinoma with EGFR mutation: how important is therapy with erlotinib compared to radiotherapy?].

Clemens Seidel, Rolf-Dieter Kortmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25793246     DOI： 10.1007/s00066-014-0772-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  11 in total

1.  EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

Authors:  April F Eichler; Kristopher T Kahle; Daphne L Wang; Victoria A Joshi; Henning Willers; Jeffrey A Engelman; Thomas J Lynch; Lecia V Sequist
Journal:  Neuro Oncol       Date:  2010-07-13       Impact factor: 12.300

2.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma.

Authors:  Shingo Matsumoto; Kenji Takahashi; Reika Iwakawa; Yoshihiro Matsuno; Yukihiro Nakanishi; Takashi Kohno; Eiji Shimizu; Jun Yokota
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Authors:  S J Park; H T Kim; D H Lee; K P Kim; S-W Kim; C Suh; J S Lee
Journal:  Lung Cancer       Date:  2012-06-05       Impact factor: 5.705

5.  Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.

Authors:  Joline S W Lind; Frank J Lagerwaard; Egbert F Smit; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

6.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Authors:  James W Welsh; Ritsuko Komaki; Arya Amini; Mark F Munsell; Wyatt Unger; Pamela K Allen; Joe Y Chang; Jeffrey S Wefel; Susan L McGovern; Linda L Garland; Su S Chen; Jamie Holt; Zhongxing Liao; Paul Brown; Erik Sulman; John V Heymach; Edward S Kim; Baldassarre Stea
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

7.  Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.

Authors:  Chien-Hung Gow; Chun-Ru Chien; Yih-Leong Chang; Yueh-Hsia Chiu; Sung-Hsin Kuo; Jin-Yuan Shih; Yeun-Chung Chang; Chong-Jen Yu; Chih-Hsin Yang; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

Authors:  Paul W Sperduto; Meihua Wang; H Ian Robins; Michael C Schell; Maria Werner-Wasik; Ritsuko Komaki; Luis Souhami; Mark K Buyyounouski; Deepak Khuntia; William Demas; Sunjay A Shah; Lucien A Nedzi; Gad Perry; John H Suh; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-04       Impact factor: 7.038

9.  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Authors:  Y-L Wu; C Zhou; Y Cheng; S Lu; G-Y Chen; C Huang; Y-S Huang; H-H Yan; S Ren; Y Liu; J-J Yang
Journal:  Ann Oncol       Date:  2012-11-04       Impact factor: 32.976

10.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.